Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Account Payables

Amounts the company owes suppliers for goods and services received.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Account Payables · Q2 FY2026 · quarter ended Jun 2026

Account payables of $6M in Q2 FY2026

Q2 FY2026 account payables was $6M.

Context

  • Account payables amounted to 4.7% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$6M+134.4% QoQ
Last fiscal yearDec 2025
$3.55M-14.2% YoY
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-14.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
3.55M USD
Year-over-year change
-14.2%
1-year CAGR
-14.2%

Account Payables vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Account payables amounts to 4.7% of total assets for ATTO, versus a peer median of 2.3%.
ATTO Competitors
Account Payables for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MLTXMoonLake ImmunotherapeuticsMar 2026$23.38M USD+132.4%—5.8%
ACRSAclaris Therapeutics, Inc.Mar 2026$14.73M USD+131.8%+8.3%7.4%
ORKAOruka Therapeutics, Inc.Sep 2026$14.38M USD+551.1%+131.7%1.2%
ALMSAlumis Inc. Common StockJun 2026$12.8M USD-14.6%+80.4%2.3%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€7.58M EUR——4.6%
ANABAnaptysBio, Inc.Mar 2026$7.52M USD+22.8%+11.6%2.3%
ATTOAttovia Therapeutics, Inc.Jun 2026$6M USD——4.7%
EVMNEvommune, Inc.Mar 2026$4.05M USD-46.6%—1.3%
ZURAZura Bio LimitedMar 2026$2.08M USD+66.8%-14.0%0.9%
CNTBConnect Biopharma Holdings LimitedDec 2025$1.96M USD+474.3%-45.2%3.5%
QTTBQ32 Bio Inc.Mar 2026$653K USD-75.9%-15.1%1.0%
Peer median (excluding ATTO) —+66.8%+8.3%2.3%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.